@Article{,
AUTHOR = {Blair Stocks, Hunter Fuentes, Zachary McDowell, Michael Brooks, Jeffrey A. Jones},
TITLE = {Oncogene targeted therapy for metastatic primary scrotal melanoma},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {28},
YEAR = {2021},
NUMBER = {2},
PAGES = {10643--10647},
URL = {http://www.techscience.com/CJU/v28n2/60340},
ISSN = {1488-5581},
ABSTRACT = {Primary scrotal melanoma represents the rarest 
genitourinary malignancy. We describe the 25th reported 
case. The 79-year-old patient presented with a rapidly 
enlarging right cutaneous scrotal mass which after local 
excision demonstrated pT4b nodular malignant melanoma 
(BRAF V600E mutation positive). The patient underwent wide local excision of his hemiscrotum and inguinal lymph 
node dissection demonstrating nodes positive for melanoma 
(pN2b). Postoperatively, the patient developed a left sided 
malignant pleural effusion (M1b). Per American Joint 
Commission Cancer staging, BRAF mutant targeted 
therapy (dabrafenib) was initiated. This case documents 
the first instance in which metastatic scrotal melanoma will 
be treated with oncogene targeted therapy.},
DOI = {}
}